Idiopathic Pulmonary Fibrosis in Switzerland: Diagnosis and Treatment

Publication

Idiopathic Pulmonary Fibrosis in Switzerland: Diagnosis and Treatment

Journal Paper/Review - Mar 25, 2017

Funke-Chambour Manuela, Geiser Thomas, Tamm Michael, Soccal Paola M, Nicod Laurent P, Kleiner-Finger Rebekka, Hostettler Katrin, Clarenbach Christian F, Brutsche Martin, Bridevaux Pierre-Olivier, Boehler Annette, Benden Christian, Barazzone-Argiroffo Constance, Adler Dan, Azzola Andrea, Lazor Romain

Citation

Funke-Chambour M, Geiser T, Tamm M, Soccal P, Nicod L, Kleiner-Finger R, Hostettler K, Clarenbach C, Brutsche M, Bridevaux P, Boehler A, Benden C, Barazzone-Argiroffo C, Adler D, Azzola A, Lazor R. Idiopathic Pulmonary Fibrosis in Switzerland: Diagnosis and Treatment. Respiration 2017; 93:363-378.

Type

Journal Paper/Review (English)

Journal

Respiration 2017; 93

Publication Date

Mar 25, 2017

Issn Electronic

1423-0356

Pages

363-378

Brief description/objective

Idiopathic pulmonary fibrosis (IPF) is a severe progressive and irreversible lung disease. Novel antifibrotic drugs that slow disease progression are now available. However, many issues regarding patient management remain unanswered, such as the choice between available drugs, their use in particular subgroups and clinical situations, time of treatment onset, termination, combination or switch, or nonpharmacologic management. To guide Swiss respiratory physicians in this evolving field still characterized by numerous areas of uncertainty, the Swiss Working Group for interstitial and rare lung diseases of the Swiss Respiratory Society provides a position paper on the diagnosis and treatment of IPF.